Pursuant to Louisiana’s medical marijuana law, commonly known as the “Alison Neustrom Act” or simply the “Act”, both physicians and patients now face novel legal situations.
Under the purview of this Act, Louisiana physicians who are registered with the Louisiana State Board of Medical Examiners are allowed to recommend certain forms of cannabis for therapeutic use to patients suffering from certain debilitating conditions. It is important to note, however, that physicians can only recommend these forms of cannabis – not prescribe them.
For patients to avail themselves of medical marijuana, they must meet these physician recommendations at a pharmacy holding one of ten primary medical marijuana pharmacy permits issued by the state. Understandably, this new legal landscape may complicate matters for law firms and companies involved in the health industry, requiring a thorough understanding of the new regulatory dynamics, in addition to the potential legal pitfalls.
This amendment becomes effective on August 1, 2022, bringing about significant changes to physician-patient relations and the broader pharmaceutical sphere within the state of Louisiana. What was once a purely clinical decision, concerning only physicians and their patients, now has a legal dynamic to it, with significant implications for the business practices of pharmacies within the state.
As the Act stands as a clear departure from traditional pharmaceutical norms, legal practitioners within this sector must engage in significant preparation to effectively navigate this new legal terrain. This novel scenario signifies a compelling intersection of health law, regulatory compliance, and liability considerations – all areas of legal practice that are expected to see a flurry of activity in the coming months.